Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somaxon Sleep Aid Silenor Not Effective, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.

You may also be interested in...



Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch

Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.

Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch

Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.

FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo

FDA’s second “complete response” letter for Transcept Pharmaceuticals’s Intermezzo continues the strict scrutiny the agency has given recent candidates for sleep maintenance insomnia indications.

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel